In this issue of Cancer Cell, Li et al. and Seckinger et al. describe promising results of two T-cell-dependent bi-specific antibodies for the treatment of multiple myeloma: one targets FcRH5 expressed on B cells, whereas the other targets the B cell maturation antigen expressed on plasma cells.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Mar 13 2017|
ASJC Scopus subject areas
- Cell Biology
- Cancer Research